Alzamend Neuro

Q1 FY2027 EarningsQ1 FY27 results missed consensus on the bottom line, reporting a GAAP net loss of $3.03M compared to the expected $2.70M loss. GAAP EPS was -$0.68 vs. the -$0.56 consensus, driven primarily by a 102% YoY surge in General and Administrative (G&A) expenses linked to ongoing litigation. Revenue remains zero, in line with expectations for this clinical-stage biopharmaceutical firm. While R&D expenses fell 38% YoY to $1.09M, total operating losses widened, though a significant $7.5M Series D preferred stock issuance on the final day of the quarter notably bolstered the cash position to $7.6M.